Please assess the completion status of the following clinical trial:

Trial Title: Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Documented HIV-1 seropositive~* Not on HIV-1 antiretroviral therapy nor planning to initiate antiretroviral therapy during the study period~* Detectable HIV-1 plasma viral load~* HSV-2 seropositive as determined by western blot~* Not intending to move out of the area for the duration of study participation~* Willing and able to provide independent written informed consent~* Willing and able to undergo clinical evaluations~* Willing and able to take study drug as directed~* Willing and able to adhere to follow-up schedule~Exclusion Criteria:~* Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir~* Planned open label use of acyclovir, valacyclovir, or famciclovir~* History of evidence of CMV disease~* Known medical history of seizures~* Known renal insufficiency, defined as serum creatinine greater than 1.5 mg/dl~* AST or ALT greater than 3 times upper limit of normal~* Hematocrit less than 30 %~* Neutropenia, defined as absolute neutrophil count less than 1000~* Thrombocytopenia, defined as platelet count less than 75,000~* History of thrombotic microangiopathy~* For women, pregnancy as confirmed by a urine pregnancy test~* Any other condition which, in the opinion of the principal investigator, may compromise the ability to follow study procedures and complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard-dose acyclovir (Type: ACTIVE_COMPARATOR): acyclovir 400 mg orally twice daily for 12 weeks.
- High-dose valacyclovir (Type: EXPERIMENTAL): valacyclovir 1000 mg orally twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).